Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma.

Carolyn RathClaude YooHalle CheplowitzMimi LoRebecca YoungJulie GuglielmoIla M SaundersRahul BanerjeeRichard YoungAnupama KumarAlfred ChungAaron Seth RosenbergCaitlin CostelloJeffrey FineMachelle WilsonNimish PatelMarisela Tan Banez

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

lenalidomide dose reductions based on patient co-morbidities or performance status may not substantially affect the duration of lenalidomide maintenance.

Keyphrases

multiple myeloma
stem cells
case report
bone marrow
cell therapy
chronic lymphocytic leukemia
low dose
mesenchymal stem cells
high dose